Incorporating Toxicity Considerations Into the Design of Two-Stage Phase II Clinical Trials

DOI10.2307/2533268zbMath0871.62090OpenAlexW1980032822WikidataQ70971469 ScholiaQ70971469MaRDI QIDQ4335635

Publication date: 12 June 1997

Published in: Biometrics (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.2307/2533268

zbMATH Keywords

group sequential designs phase II trials early stopping toxicity multiple endpoints control of error rates clinical response maximum expected accrual Simon designs two-stage clinical trials

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Sequential statistical analysis (62L10)

Related Items (19)

A curtailed procedure for selecting among treatments with two Bernoulli endpoints ⋮ Two-stage phase II trials with early stopping for effectiveness and safety as well as ineffectiveness or harm ⋮ Exact power calculations for detecting hypotheses involving two correlated binary outcomes ⋮ Bayesian predictive monitoring with bivariate binary outcomes in phase II clinical trials ⋮ Finding confidence bound using two-stage data ⋮ Some geometric methods for constructing decision criteria based on two-dimensional parame\-ters ⋮ On the maximum total sample size of a group sequential test about bivariate binomial propor\-tions ⋮ Ethical issues in oncology biostatistics ⋮ Treatment Comparisons Based on Two‐Dimensional Safety and Efficacy Alternatives in Oncology Trials ⋮ Decision Theoretic Designs for Phase II Clinical Trials with Multiple Outcomes ⋮ Bayesian randomized clinical trials: A decision-theoretic sequential design ⋮ A Bayesian Group Sequential Approach for Multiple Endpoints ⋮ Decision-Theoretic Designs for Pre-Phase II Screening Trials in Oncology ⋮ Monitoring the Rates of Composite Events with Censored Data in Phase II Clinical Trials ⋮ Directed Walk Designs for Dose-Response Problems with Competing Failure Modes ⋮ A Geometric Approach to Comparing Treatments for Rapidly Fatal Diseases ⋮ Efficacy and toxicity monitoring via Bayesian predictive probabilities in phase II clinical trials ⋮ Testing Statistical Hypotheses on Stochastic Ordering of Discrete Distributions ⋮ A review of phase 2-3 clinical trial designs

This page was built for publication: Incorporating Toxicity Considerations Into the Design of Two-Stage Phase II Clinical Trials